CN115487221A - 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 - Google Patents
一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN115487221A CN115487221A CN202211128626.1A CN202211128626A CN115487221A CN 115487221 A CN115487221 A CN 115487221A CN 202211128626 A CN202211128626 A CN 202211128626A CN 115487221 A CN115487221 A CN 115487221A
- Authority
- CN
- China
- Prior art keywords
- blue light
- medicine
- retina
- composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 230000006378 damage Effects 0.000 title claims abstract description 38
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 34
- 208000014674 injury Diseases 0.000 title claims abstract description 34
- 210000001525 retina Anatomy 0.000 title claims abstract description 31
- 235000013305 food Nutrition 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 34
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 29
- 235000012680 lutein Nutrition 0.000 claims abstract description 28
- 239000001656 lutein Substances 0.000 claims abstract description 28
- 229960005375 lutein Drugs 0.000 claims abstract description 28
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 28
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 28
- 235000015097 nutrients Nutrition 0.000 claims abstract description 20
- 235000010208 anthocyanin Nutrition 0.000 claims abstract description 17
- 239000004410 anthocyanin Substances 0.000 claims abstract description 17
- 229930002877 anthocyanin Natural products 0.000 claims abstract description 17
- 150000004636 anthocyanins Chemical class 0.000 claims abstract description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 16
- 235000016357 Mirtillo rosso Nutrition 0.000 claims abstract description 12
- 244000077923 Vaccinium vitis idaea Species 0.000 claims abstract description 12
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 claims abstract description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 8
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 7
- 239000003765 sweetening agent Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 21
- 239000012071 phase Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 18
- 108010046377 Whey Proteins Proteins 0.000 claims description 14
- 102000007544 Whey Proteins Human genes 0.000 claims description 14
- 235000021119 whey protein Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- 229920002774 Maltodextrin Polymers 0.000 claims description 10
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 10
- 235000021323 fish oil Nutrition 0.000 claims description 10
- 229920002414 procyanidin Polymers 0.000 claims description 10
- 239000005913 Maltodextrin Substances 0.000 claims description 9
- 229940035034 maltodextrin Drugs 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 7
- 235000012041 food component Nutrition 0.000 claims description 6
- 239000004376 Sucralose Substances 0.000 claims description 5
- 239000007908 nanoemulsion Substances 0.000 claims description 5
- 235000019408 sucralose Nutrition 0.000 claims description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 240000000851 Vaccinium corymbosum Species 0.000 claims 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims 1
- 235000021014 blueberries Nutrition 0.000 claims 1
- 230000008832 photodamage Effects 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000006870 function Effects 0.000 abstract description 9
- 230000003078 antioxidant effect Effects 0.000 abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 235000006708 antioxidants Nutrition 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000003094 microcapsule Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 239000000047 product Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 7
- 229940118019 malondialdehyde Drugs 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000002207 retinal effect Effects 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 4
- 206010057430 Retinal injury Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000000940 FEMA 2235 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000083879 Polyommatus icarus Species 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000019209 bilberry extract Nutrition 0.000 description 1
- 229940102480 bilberry extract Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用,属于药食两用技术领域,本发明的具有抵御视网膜蓝光损伤的药食两用组合物,包括以下重量份组分:微囊化营养组分40~60份,甜味剂1~3份,微晶纤维素10~20份,硬脂酸镁0.5~2份;该药食两用组合物产品制备简单快捷,绿色健康无副作用;通过微囊化营养组分的添加,显著提高了原花青素、越橘花色苷及叶黄素的稳定性及生物利用度,并充分发挥其协同抗炎抗氧化功能,具有预防和改善由LED蓝光照射引起的视网膜损伤等问题,具有广阔的应用前景及经济效益。
Description
技术领域
本发明涉及一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用,属于药食两用技术领域。
背景技术
蓝光(400–500nm,BL)是可见光光谱中波长较短且能量较高的光线。近年来,电视机、智能手机和电脑等电子设备的使用需求逐渐增多,导致人体受蓝光的照射量不断增加。研究表明,蓝光照射可诱导氧化应激、炎症,损害视网膜色素上皮细胞(RPE)的功能,降低细胞膜完整性,最终导致细胞凋亡;此外,蓝光可导致光感受器变性和凋亡,从而引发如年龄相关性黄斑病变(AMD)等眼部疾病。
叶黄素(lutein)是一种天然类胡萝卜素色素,也是构成人眼视网膜黄斑区域的主要色素,具有多种护眼功能,如清除人体内的自由基、预防黄斑变性、保护视网膜色素上皮细胞免受光氧化等。人体无法自身合成叶黄素,必须通过食物摄取。然而,叶黄素易受环境因素如光照、氧气、温度等发生降解,失去功能活性,同时叶黄素较差的溶解性也限制了其在人体内的利用。
传统药食两用组合物一般以补充能量、放松身心、改善口味为主,近年来,随着社会的进步,人们对于自身健康问题越来越重视,开发具有保健功能性的休闲食品成为了社会关注的焦点。功能性糖果不仅具有传统糖果基本特征,又能调节人体特定生理功能,促进人体健康、预防疾病,具有突出的开发价值。中国专利CN109845868A的专利申请,公开了一种改善视疲劳的叶黄素酯压片糖果及其制备方法,该发明以叶黄素酯、玉米黄质、DHA及β-类胡萝卜素为主要功能原料,其制备方法简单,具有能够缓解视疲劳等问题。然而,其制备过程仅仅依靠原辅料的简单配比,直接压片成品,并未解决功能性原料溶解性及生物利用度等关键问题,并且也未针对性的从根本上解决普遍的蓝光对视网膜损伤的问题。
直接压片法无需通过制粒等加工工艺,可直接将主要原料与辅料混合压片。其特点为工艺步骤简单快捷,生产效率高,但对加工粉末的含水量及成分具有较高要求,现主要适用于遇湿热不稳定的原料。
因此,针对以上问题及人们对休闲食品功能化的追求,开发一种具有保护视力,能够抵御蓝光视网膜损伤作用的功能性休闲食品极为重要。
发明内容
针对现有技术存在的不足与缺陷,本发明提供一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用,本发明利用乳清分离蛋白和多酚类物质作为壁材,通过原花青素及越橘花色苷与蛋白非共价交联,在提高蛋白的乳化特性的同时,引入了具有优秀抗氧化功能的植物多酚,且能够很好的保持芯材叶黄素的功能特性;所得产品包埋率较高且结构稳定;操作方法稳定高效、无污染,有效提高了叶黄素在人体摄入后的生物利用度,对蓝光损伤性视网膜具有很好的预防和修复作用。
本发明的第一个目的是提供一种具有抵御视网膜蓝光损伤的药食两用组合物,所述药食两用组合物包括以下重量份原料制成:微囊化营养组分40~60份,甜味剂1~3份,微晶纤维素10~20份,硬脂酸镁0.5~2份。
在一种实施方式中,所述微囊化营养组分包括乳清分离蛋白、原花青素、越橘花色苷、深海鱼油、叶黄素及麦芽糊精。
在一种实施方式中,所述甜味剂包括三氯蔗糖、阿斯巴甜、三氯蔗糖和木糖醇中的一种或多种。
在一种实施方式中,所述微囊化营养组分的制备方法,包括以下步骤:
S1:将叶黄素溶于深海鱼油中,作为油相;
S2:将乳清分离蛋白、原花青素、越橘花色苷及麦芽糊精溶于水中,室温下搅拌混合,作为水相;
S3:将步骤S1中所得油相与步骤S2中所得水相按照体积比为1:19~3:17混合,剪切乳化、均质,得到纳米乳液;
S4:将S3所得纳米乳液利用喷雾干燥法去除水分,即得到微囊化营养组分。
在一种实施方式中,步骤S1中,所述叶黄素与深海鱼油质量体积比为0.01~0.1:1g/ml。
在一种实施方式中,步骤S2中,所述水相为每95mL溶液含有乳清分离蛋白2~7g,原花青素2~7g,越橘花色苷0.1~1g,麦芽糊精5~20g,混合时间3~5h。
在一种实施方式中,步骤S3中,所述剪切采用高速分散机进行,转速为10000~12000rpm,时间为1~2min。
在一种实施方式中,所述均质通过高压均质机均质,压力为400~600bar,时间为1~2min。
在一种实施方式中,步骤S4中,所述喷雾干燥条件为进风温度130~150℃,蠕动泵转速为8~10R/min。
本发明的另一目的是提供一种具有抵御视网膜蓝光损伤的药食两用组合物的制备方法,所述方法包括:将微囊化营养组分和甜味剂混合,翻转搅拌10~30min,混合均匀;然后加入微晶纤维素,持续翻转搅拌10~20min;再加入硬脂酸镁,翻转搅拌5~10min,然后将混合物采用压片机直接压片,即得具有抵御视网膜蓝光损伤的药食两用组合物。
本发明的第三个目的是提供一种由上述所述的药食两用组合物在制备抵御视网膜蓝光损伤的药品中的应用。
本发明的有益效果:
(1)本发明制备方法简单快捷,加工过程中不需添加任何化学试剂,所得产品绿色健康。
(2)本产品所得微囊化营养组分,尺寸分布均匀,分散性良好,能够提高叶黄素等有效成分稳定性,改善其水溶性,从而提高口服生物利用度;
(3)本产品中通过将原花青素及越橘花色苷与乳清分离蛋白非共价结合形成壁材,充分发挥植物多酚与叶黄素的协同功效。
(4)本发明制备的药食两用组合物,具有优秀的抗氧化及抗炎效果,可以有效缓解和预防由LED蓝光照射引发的视网膜损伤的症状,且产品无任何副作用。
附图说明
图1为本发明实施例1中微囊化营养组分的扫描电镜及其放大图;
图2为本发明实施例1中微囊化营养组分的平均粒径及分散指数;
图3为本发明实施例1和对比例1制备的产品对RAW 264.7巨噬细胞活力对比图;
图4为本发明实施例1和对比例例1制备的产品对RAW 264.7细胞炎症模型中肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、白介素-1β(IL-1β)、白介素-10(IL-10)调控含量变化对比图;
图5为本发明实施例1和对比例例1制备的产品对RAW 264.7细胞总抗氧化能力(T-AOC)含量调控变化对比图;
图6为本发明实施例1和对比例例1制备的产品对各组小鼠血清GSH含量调控的变化对比图;
图7为本发明实施例1和对比例例1制备的产品对各组小鼠血清丙二醛(MDA)含量调控的变化对比图;
图8为本发明实施例1和对比例例1制备的产品对各组小鼠血清超氧化物歧化酶(SOD)含量调控变化对比图;
图9为本发明实施例1和对比例例1制备的产品对各组小鼠视网膜组织H&E染色变化对比图。
具体实施方式
下面结合具体实施例对本发明作进一步的详细描述,但本发明的实施方式不限于这些实例。
实施例中所用叶黄素(纯度>75%)购自于上海麦克林生化科技有限公司;
原花青素(纯度>95%)购自于天津尖峰天然产物研究开发有限公司;
越橘花色苷(花色苷纯度>36%,花青素纯度>25%)购自于西安佰斯特生物科技有限公司;
乳清分离蛋白(纯度80%)购自于源叶生物科技有限公司;
麦芽糊精(纯度为99%)购自于北京索莱宝科技有限公司;
微晶纤维素(食品级)购自于青岛万源山生物科技有限公司;
深海鱼油购自于美国Piping Rock大通路国际有限公司。
实施例1
一种具有抵御视网膜蓝光损伤的药食两用组合物的制备方法,具体包括如下步骤:
(1)将0.15g叶黄素溶于5mL深海鱼油中,作为油相;
(2)将乳清分离蛋白3g、原花青素2.7g、越橘花色苷0.3g及麦芽糊精14g溶于95mL去离子水中,室温下充分搅拌混合3h,作为水相;
(3)将步骤(1)所得油相与步骤(2)所得水相按照体积比为1:19(v/v,ml/ml)混合,利用高速分散机以12000rpm剪切乳化2min后,将所得乳化后的乳液通过高压均质机以500bar均质2min,得到纳米乳液;
(4)将步骤(3)所得纳米乳液以进风温度150℃,蠕动泵转速10R/min的干燥条件喷雾干燥去除水分,得到微囊化营养组分;
(5)1份以1g计:称取步骤(4)制备的微囊化营养组分50份和三氯蔗糖2份,翻转搅拌20min,混合均匀;然后加入微晶纤维素20份,持续翻转搅拌10min;再加入硬脂酸镁1份,翻转搅拌5min,混合均匀,得混合物;
(6)将步骤(5)的混合物直接压片,得到具有抵御视网膜蓝光损伤的药食两用组合物。
通过利用乳清分离蛋白与植物多酚非共价结合,既增强了蛋白质的乳化能力,又稳定了原花青素和越橘花色苷,再经过均质乳化,喷雾干燥的方式将叶黄素成功负载,实现了对三种活性物质的保护作用,最终得到的微囊化营养组分为纳米级球形结构,结构稳定,粒径为150~302nm;微囊化营养组分的扫描电镜及其放大图如图1所示。
本实施例所制备的微囊化营养组分的粒径分布图和分散指数如图2所示,经过动态光散射测量可知,所得组分平均尺寸为212.55nm,分散系数PDI为0.82。说明表面活性物质乳清分离蛋白与植物多酚共价结合,可作为优秀的“壁材”,从而防止乳液液滴直接相互聚集,使微囊化营养组分具有良好的稳定性。
实施例2
一种具有抵御视网膜蓝光损伤的药食两用组合物的制备方法,具体包括如下步骤:
(1)将0.20g叶黄素溶于5mL深海鱼油中,作为油相;
(2)将乳清分离蛋白4g、原花青素3.6g、越橘花色苷0.4g及麦芽糊精12g溶于95mL去离子水中,室温下充分搅拌混合4h,作为水相;
(3)将步骤(1)所得油相与步骤(2)所得水相按照体积比为1:19(v/v,ml/ml)混合,利用高速分散机以11000rpm剪切乳化1.5min后,将所得乳化后的乳液通过高压均质机以400bar均质1.5min,得到纳米乳液;
(4)将步骤(3)所得纳米乳液以进风温度140℃,蠕动泵转速9R/min的干燥条件喷雾干燥去除水分,得到微囊化营养组分;
(5)1份以1g计:称取步骤(4)制备的微囊化营养组分40份和阿斯巴甜、三氯蔗糖和木糖醇各1份,翻转搅拌30min,混合均匀;然后加入微晶纤维素15份,持续翻转搅拌15min;再加入硬脂酸镁1.5份,翻转搅拌5min,混合均匀,得混合物;
(6)将步骤(5)的混合物直接压片,得到具有抵御视网膜蓝光损伤的药食两用组合物。
实施例3
一种具有抵御视网膜蓝光损伤的药食两用组合物的制备方法,具体包括如下步骤:
(1)将0.25g叶黄素溶于5mL深海鱼油中,作为油相;
(2)将乳清分离蛋白5g、原花青素4.5g、越橘花色苷0.5g及麦芽糊精10g溶于95mL去离子水中,室温下充分搅拌混合5h,作为水相;
(3)将步骤(1)所得油相与步骤(2)所得水相按照体积比为1:19(v/v,ml/ml)混合,利用高速分散机以10000rpm剪切乳化1min后,将所得乳化后的乳液通过高压均质机以600bar均质2min,得到纳米乳液;
(4)将步骤(3)所得纳米乳液以进风温度130℃,蠕动泵转速8R/min的干燥条件喷雾干燥去除水分,得到微囊化营养组分;
(5)1份以1g计:称取步骤(4)制备的微囊化营养组分40份和阿斯巴甜1份,翻转搅拌10min,混合均匀;然后加入微晶纤维素10份,持续翻转搅拌10min;再加入硬脂酸镁2份,翻转搅拌10min,混合均匀,得混合物;
(6)将步骤(5)的混合物直接压片,得到具有抵御视网膜蓝光损伤的药食两用组合物。
对比例1
市售产品:汤臣倍健股份有限公司生产的越橘叶黄素酯β-胡萝卜素软胶囊,专利公布号为:CN113475714A;产品主要原料为:越橘提取物、叶黄素酯、天然β-类胡萝卜素油、大豆油、蜂蜡、天然维生素E、明胶、纯化水、甘油、焦糖色。
性能结果测定
将实施例1制备的具有抵御视网膜蓝光损伤的药食两用组合物同对比例1中的产品进行以下细胞和动物测试;
其中涉及的培养基为含有体积分数10%胎牛血清和1%商品化抗生素(青霉素和链霉素混合液;SV30010;北京宝希迪有限公司)的高糖培养基(dulbecco's modifiedeagle medium,DMEM);
TNF-α、IL-6、IL-1β、IL-10、T-AOC及GSH检测试剂盒均购自于南京建成生物工程研究所有限公司。
1、具有抵御蓝光损伤作用的药食两用组合物对细胞活力的影响
测试细胞为RAW 264.7小鼠源单核巨噬细胞,细胞实验具体如下:将细胞悬液100μL接种于96孔板中(细胞密度1×104个/mL),在37℃,5%CO2细胞培养箱内培养24h;待细胞贴壁完全后,弃取培养基后分别加入用新培养基稀释的不同浓度的实施例1和对比例1的产品溶液100μL(溶液中有效叶黄素浓度为0,40,50,60,80和100μg/mL),静置孵育24h后,加入20μL浓度为5μg/mL的MTT进一步孵育4h,除去上清液后,加入150μL二甲基亚砜(DMSO),充分震荡15min后通过酶标仪在570nm处测定吸光度,检测细胞活力。
图3为实施例1、对比例1对RAW 264.7巨噬细胞活力对比图;如图所示,二者在RAW264.7细胞活力MTT实验上均表现为低浓度下,细胞活力与给药浓度成正比,但对比例1所应用的汤臣倍健越橘叶黄素β-类胡萝卜素软胶囊在100μg/mL的高浓度下,细胞存活率显著下降,对细胞具有明显的损伤作用。实施例1所制备的样品在100μg/mL的浓度下对细胞增殖效果远高于对比例1(P≤0.05),上述细胞实验结果表明,本实施例制备的产品对细胞全浓度范围无毒性,且在较高浓度下可以更好被细胞吸收,提高细胞增殖能力,有利于高浓度摄取。
2、具有抵御蓝光损伤作用的药食两用组合物在细胞水平上的抗炎能力评估
测试细胞为RAW264.7小鼠源单核巨噬细胞,细胞实验具体如下:将细胞悬液2mL接种于6孔板中(细胞密度1×106个/mL),在37℃,5%CO2细胞培养内培养24h,待完全贴壁后,空白组更换新培养基,测试组更换含有测试样品(叶黄素浓度100μg/mL)的新培养基溶液,同时,加入1ng/mL的LPS共孵育(对照组不添加测试样品)。24h后收集细胞悬液,离心后取上清,并测定验证相关因子TNF-α、IL-6、IL-1β及IL-10含量。
图4为LPS诱导的RAW 264.7细胞炎症模型中炎症相关因子含量变化对比图。如图所示,与空白组相比,利用LPS刺激RAW 264.7细胞后,对照组的促炎因子(IL-6,IL-1β)水平显著提高(P≤0.05),而抑炎因子(IL-10)水平降低。经二种产品处理后,与对照组相比,细胞TNF-α和IL-1β水平均有显著下降(P≤0.05),恢复至接近空白组。
实施例1组中促炎症因子IL-6水平略低于对比例1组,而抑炎细胞因子(IL-10)水平则明显高于对比例1组。以上结果表明,实施例1所制备的具有抵御蓝光损伤作用的药食两用组合物具有良好的抗炎效果,可以显著减轻由LPS刺激引发的细胞炎症程度。
表1、实施例1及对比例1在细胞炎症模型中炎症因子释放量
3、具有抵御蓝光损伤作用的药食两用组合物在细胞水平上的抗氧化能力评估
测试细胞为RAW264.7小鼠源单核巨噬细胞,细胞实验具体如下:将细胞悬液100μL接种于96孔板中(细胞密度1×104个/mL),在37℃ 5%CO2细胞培养箱内培养24h。待细胞贴壁完全后,空白组更换新培养基,测试组更换含有测试样品(叶黄素浓度100μg/mL)的新培养基溶液,同时,加入500μmol/L的H2O2共孵育(对照组不添加测试样品)。12h后利用MTT法测定细胞活力。
将细胞悬液2mL接种于6孔板中(细胞密度1×106个/mL),在37℃,5%CO2细胞培养箱内培养24h,待细胞完全贴壁后,空白组更换新培养基,测试组更换含有测试样品(叶黄素浓度100μg/mL)的新培养基溶液,同时,加入500μmol/L的H2O2共孵育(对照组不添加测试样品)。12h后弃去培养基,利用PBS清洗孔板内部后,将细胞利用细胞刮刀挂下,利用超声破碎法获得细胞破碎液并测定T-AOC及GSH含量。
T-AOC反映了细胞清除自由基和抑制脂质过氧化的能力,如图5所示,经实施例1组处理后,细胞T-AOC水平显著高于对比例1产品(P≤0.05)。
综上,实施例1所制备的具有抵御蓝光损伤作用的药食两用组合物具有优秀的体外抗氧化效果,可以显著提高细胞在损伤条件下的总抗氧化能力及清除自由基能力。
4、具有抵御蓝光损伤作用的药食两用组合物对LED蓝光损伤模型小鼠的视网膜影响
选用Balb/c 5周龄雄性小鼠(购自于辽宁长生生物技术股份有限公司);所有动物实验均按照1986年《英国动物(科学程序)法》和相关指南、欧盟指令2010/63/EU进行,并且该指南和动物方案(Dlpu2020024)已获得大连工业大学伦理委员会的批准。
将小鼠饲养在标准笼中,并在25±1℃下保持12:12小时的明暗循环饲养。在自由饮食、饮水适应1周后,将小鼠随机分为五组(每组6只小鼠)。
空白组和对照组:小鼠每天灌胃200μL纯净水。
测试组1:小鼠每天灌胃200μL实施例1产品水溶液(100mg/kg小鼠体重);
测试组2:小鼠每天灌胃200μL实施例1产品水溶液(50mg/kg小鼠体重);
测试组3:小鼠每天灌胃200μL对比例1产品水溶液(50mg/kg小鼠体重);
在连续灌胃5天后,除空白组外,其余各组小鼠在灌胃后暗室放置1h,随后暴露在7000lx光强的蓝光灯带下照射1h,5天后将蓝光照射时长增加至2h。高时长照射9天后对小鼠进行眼球取血获取血样并离心,取血清测定GSH、MDA及SOD含量。将摘除的眼球固定在Davidson's溶液固定液中(10%中性缓冲甲醛:95%乙醇:冰醋酸:蒸馏水体积比为1:3:1:3,吉加生物科技有限公司,辽宁)。随后取出进行石蜡包埋,切片,脱水、固定,用苏木精和伊红(H&E)染色,以60mm的间隔测量据视神经600至900mm处的视网膜组织。外核层(ONL)、内核层(INL)、感光层(PL)和整个视网膜的厚度使用Image J软件进行计算。
小鼠血清中GSH含量变化对比如图6所示。GSH被认为是维持生物体内氧化还原平衡的重要因子之一,经灌胃治疗后,测试组2中血清GSH含量最高,且与测试组3具有显著性差异(P≤0.05)。
MDA是脂质过氧化产物,MDA水平高低间接反映机体细胞受自由基攻击的严重程度,如图7所示,经LED蓝光照射后,小鼠血清中MDA水平显著增高,表明LED蓝光可引起机体氧化损伤,经灌胃治疗后,MDA含量均显著下调并恢复至接近空白组水平。
同样,SOD间接反映了机体清除氧自由基的能力,如图8所示,相比于对照组,测试组2小鼠血清中SOD含量显著升高(P≤0.05)。小鼠血清相关数据显示,实施例1所制备产品具有明显清除体内自由基,抗氧化等能力。
图9为小鼠的视网膜组织切片H&E染色图,测量结果显示,LED蓝光照射后视网膜总厚度及视网膜组成部分厚度均显著变薄,经测试组1和测试组2治疗后,包括感光层、外核层、内核层及视网膜总厚度,均有显著恢复且与测试组3和对照组均具有显著性差异。
小鼠动物实验结果表明,实施例1所制备的具有抵御蓝光损伤作用的药食两用组合物具有明显有效地抵御LED蓝光照射引起的视网膜损伤的功能,且综合效果高于对比例所述两种商品。
本申请发明通过直接压片的方法制备了具有抵御蓝光损伤作用的药食两用组合物,生产加工方式简单快捷,且无任何化学成分添加,绿色健康。同时,利用微囊化技术,实现了对叶黄素、原花青素及越橘花色苷的充分保护,提高了营养成分稳定性,并发挥其协同功效。测试结果表明,本发明产品具有优异的抗氧化抗炎效果,可以显著改善由蓝光刺激引发的视网膜损伤等问题,且综合效果高于对比例中所述市售的咀嚼片及软胶囊。
上述实施例为本发明的优选实施方式,但不限于上述实施方案中的具体条件及细节,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,所述药食两用组合物包括以下重量份原料制成:微囊化营养组分40~60份,甜味剂1~3份,微晶纤维素10~20份,硬脂酸镁0.5~2份。
2.根据权利要求1所述的具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,所述微囊化营养组分包括乳清分离蛋白、原花青素、越橘花色苷、深海鱼油、叶黄素及麦芽糊精。
3.根据权利要求1所述的具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,所述甜味剂包括木糖醇、三氯蔗糖、阿斯巴甜及山梨糖醇中的一种或几种。
4.根据权利要求1所述的具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,所述微囊化营养组分的制备方法,包括以下步骤:
S1:将叶黄素溶于深海鱼油中,作为油相;
S2:将乳清分离蛋白、原花青素、越橘花色苷及麦芽糊精溶于水中,室温下搅拌混合,作为水相;
S3:将步骤S1中所得油相与步骤S2中所得水相按照体积比为1:19~3:17混合,剪切乳化、均质,得到纳米乳液;
S4:将S3所得纳米乳液利用喷雾干燥法去除水分,即得到微囊化营养组分。
5.根据权利要求4所述的具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,所述步骤S1叶黄素与深海鱼油的质量体积比为0.01~0.1:1g/ml。
6.根据权利要求4所述的具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,步骤S2中所述水相为每95mL溶液含有乳清分离蛋白2~7g,原花青素2~7g,越橘花色苷0.1~1g,麦芽糊精5~20g。
7.根据权利要求4所述的具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,步骤S3中所述剪切乳化的转速为10000~12000rpm,时间为1~2min。
8.根据权利要求4所述的具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,步骤S3中所述均质压力为400~600bar,时间为1~2min。
9.由权利要求1~8任一项所述的具有抵御视网膜蓝光损伤的药食两用组合物的制备方法,其特征在于,所述方法包括:将微囊化营养组分和甜味剂混合,翻转搅拌10~30min,混合均匀;然后加入微晶纤维素,持续翻转搅拌10~20min;再加入硬脂酸镁,翻转搅拌5~10min,然后将混合物采用压片机直接压片,即得具有抵御视网膜蓝光损伤的药食两用组合物。
10.由权利要求1~8任一项所述的具有抵御视网膜蓝光损伤的药食两用组合物在制备低抵御视网膜蓝光损伤的药品中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211128626.1A CN115487221B (zh) | 2022-09-16 | 2022-09-16 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
PCT/CN2023/113044 WO2024055795A1 (zh) | 2022-09-16 | 2023-08-15 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211128626.1A CN115487221B (zh) | 2022-09-16 | 2022-09-16 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115487221A true CN115487221A (zh) | 2022-12-20 |
CN115487221B CN115487221B (zh) | 2023-07-18 |
Family
ID=84468767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211128626.1A Active CN115487221B (zh) | 2022-09-16 | 2022-09-16 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115487221B (zh) |
WO (1) | WO2024055795A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024055795A1 (zh) * | 2022-09-16 | 2024-03-21 | 大连工业大学 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496808A (zh) * | 2008-01-29 | 2009-08-05 | 沈阳皓天万嘉医药科技有限公司 | 一种用于视力保健的复方叶黄素微囊及其制备方法 |
WO2014076432A1 (fr) * | 2012-11-16 | 2014-05-22 | Institut National De La Recherche Agronomique - Inra | Procédé pour la fabrication d'une émulsion sèche en poudre contenant au moins un principe actif lipophile, destinée à améliorer la biodisponibilité dudit principe actif lipophile, et émulsion sèche obtenue par ce procédé |
CN109567169A (zh) * | 2018-12-29 | 2019-04-05 | 北京金康普食品科技有限公司 | 微量营养素预混料的微囊化纳米制剂及其制备方法 |
CN113115945A (zh) * | 2021-03-29 | 2021-07-16 | 湖南万象生物科技有限公司 | 一种叶黄素复方微囊粉及其制备方法与应用 |
CN114431467A (zh) * | 2022-01-28 | 2022-05-06 | 华南理工大学 | 一类食品级类胡萝卜素纳米胶囊制品及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110384235A (zh) * | 2018-04-20 | 2019-10-29 | 浙江新维士生物科技有限公司 | 改善视疲劳的食品组合物、口服制剂及其制备方法 |
CN108771243A (zh) * | 2018-05-17 | 2018-11-09 | 吉林修正健康股份有限公司 | 一种缓解视疲劳的保健食品及其制备方法 |
CN108524667A (zh) * | 2018-05-23 | 2018-09-14 | 南京中生生物科技有限公司 | 一种具有缓解视疲劳作用的叶黄素酯组合物及其制备方法 |
CN110236189A (zh) * | 2019-06-25 | 2019-09-17 | 海普诺凯营养品有限公司 | 一种保护视力的组合物及其制备方法和应用 |
CN112715729A (zh) * | 2020-12-30 | 2021-04-30 | 广东粤微食用菌技术有限公司 | 一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 |
CN115487221B (zh) * | 2022-09-16 | 2023-07-18 | 大连工业大学 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
-
2022
- 2022-09-16 CN CN202211128626.1A patent/CN115487221B/zh active Active
-
2023
- 2023-08-15 WO PCT/CN2023/113044 patent/WO2024055795A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496808A (zh) * | 2008-01-29 | 2009-08-05 | 沈阳皓天万嘉医药科技有限公司 | 一种用于视力保健的复方叶黄素微囊及其制备方法 |
WO2014076432A1 (fr) * | 2012-11-16 | 2014-05-22 | Institut National De La Recherche Agronomique - Inra | Procédé pour la fabrication d'une émulsion sèche en poudre contenant au moins un principe actif lipophile, destinée à améliorer la biodisponibilité dudit principe actif lipophile, et émulsion sèche obtenue par ce procédé |
CN109567169A (zh) * | 2018-12-29 | 2019-04-05 | 北京金康普食品科技有限公司 | 微量营养素预混料的微囊化纳米制剂及其制备方法 |
CN113115945A (zh) * | 2021-03-29 | 2021-07-16 | 湖南万象生物科技有限公司 | 一种叶黄素复方微囊粉及其制备方法与应用 |
CN114431467A (zh) * | 2022-01-28 | 2022-05-06 | 华南理工大学 | 一类食品级类胡萝卜素纳米胶囊制品及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024055795A1 (zh) * | 2022-09-16 | 2024-03-21 | 大连工业大学 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2024055795A1 (zh) | 2024-03-21 |
CN115487221B (zh) | 2023-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103735733B (zh) | 一种含叶黄素酯的复方制剂及其制备方法 | |
US9889173B2 (en) | Composition for improving macular pigment density and preventing or treating age-related macular degeneration | |
CN108157568A (zh) | 一种缓解视疲劳的组合糖果及其制备方法和用途 | |
JP7377283B2 (ja) | 人の目の水晶体及び網膜感光細胞栄養素が含まれる、目を保護し視力を良くする生薬菓子の製造方法 | |
CN103735616A (zh) | 一种用于保护视力的微囊化制剂及其制备方法 | |
WO2024055795A1 (zh) | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 | |
JPWO2017135466A1 (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
CN107410811B (zh) | 一种叶黄素微胶囊的制备方法及叶黄素微胶囊速溶饮料 | |
CN106539083A (zh) | 一种用于预防和治疗糖尿病视网膜病变、缓解视力疲劳的组合物 | |
JP6336373B2 (ja) | マリーゴールド抽出物を含有する加工食品 | |
CN110140960A (zh) | 一种改善男性勃起功能障碍、抗疲劳的组合物及制剂、饮液 | |
JP6148780B1 (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
CN111567805A (zh) | 一种水溶性雨生红球藻虾青素软胶囊及其制备方法 | |
CN115531319B (zh) | 一种高稳定性脂质体及其制备方法和用途 | |
WO2021008265A1 (zh) | 一种女性更年期抗衰老的软胶囊及其制备方法 | |
CN102429180B (zh) | 一种食用组合物及其制备方法与应用 | |
Mishra et al. | Attenuation of oxidative stress and glucose toxicity by lutein loaded nanoparticles from Spinacia oleracea leaves | |
CN109771374B (zh) | 复合雨生红球藻虾青素脂肪乳制剂及其制备方法与应用 | |
CN108338364A (zh) | 含茶氨酸和虾青素的缓解视疲劳的组合物 | |
AU2012325600A1 (en) | Pharmaceutical composition regulating blood fat and preparation process thereof | |
CN108379446B (zh) | 具有辅助治疗男性少弱精子症的辅酶q10制剂及其制备方法 | |
TWI538684B (zh) | 具有護眼功能之中藥材組成物及其製造方法 | |
CN105963389B (zh) | 栀子中抗高原缺氧疲劳活性成分的分离方法及其应用 | |
CN109770364A (zh) | 具有缓解视疲劳功能的组合物、制备方法及应用 | |
CN112843155B (zh) | 一种适合产妇用的祛斑及缓解腰痛的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |